01/06/2020 10:11 pm Welcome to isteroids.com - BLOG

Wednesday 21, Jul 2010

  B-cell depletion therapy effective for treating refractory patients

Posted By
Pin it Share on Tumblr

B-cell depletion therapy effective for treating refractory patientsAccording to a study presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain, 36 percent of patients afflicted with refractory systemic lupus erythematosus (SLE or lupus) could notice improvements after undergoing B-cell depletion therapy (BCDT) and do not feel or need standard immunosuppressive agents in the future.

It is worth noting here that reducing the number of B-cells in the system by B-cell depletion therapy is considered as a potential therapy for SLE patients who are unresponsive to other forms of treatment.

It was revealed by co-author of the paper, Professor David Isenberg, from University College London in the United Kingdom that the study results are encouraging and demonstrate that BCDT could be rated as a promising therapeutic option for lupus patients and is effective to reduce the need for continuous immunosuppressive therapy.

Friday 30, Apr 2010

  B-cell depletion therapy can help refractory patients in remaining stable

Posted By
Pin it Share on Tumblr

 

b-cell-depletion-therapy-can-help-refractory-patients-in-remaining-stableThirty six percent of patients suffering from refractory systemic lupus erythematosus (SLE or lupus) remain well after undergoing B-cell depletion therapy (BCDT) without feeling or requiring the need of further standard immunosuppressive agents. This finding was disclosed by a study presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain.

It is important to note here that minimizing the number of B-cells in the system by BCDT has been suggested as a potential therapy to SLE patients unresponsive to other treatments.

Co-author of the paper, Professor David Isenberg, from University College London in the United Kingdom, said that results are encouraging and suggest that B-cell depletion therapy is a promising therapeutic option for lupus patients besides reducing the need for continuous immunosuppressive therapy.